Patent · US Active

Dual NK1/NK3 receptor antagonists

US8404708B2 · kind B2 · utility

0Cited by

1References

2Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Torsten Hoffmann · Weil am Rhein, DE
Andreas Koblet · Bottmingen, CH
Jens-Uwe Peters · Weil am Rhein, DE
Patrick Schnider · Bottmingen, CH
Andrew Sleight · Riedisheim, FR
Heinz Stadler · Basel, CH

Key dates

Filing date	Mar 31, 2011
Grant date	Mar 26, 2013
Priority date	—
Expiry date	Mar 31, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D513/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.